26
IRUS Total
Downloads
  Altmetric

2022 FDA TIDES (peptides and oligonucleotides) harvest

File Description SizeFormat 
pharmaceuticals-16-00336.pdfPublished version8.24 MBAdobe PDFView/Open
Title: 2022 FDA TIDES (peptides and oligonucleotides) harvest
Authors: Almusaimi, O
Al Shaer, D
Albericio, F
De la Torre, BG
Item Type: Journal Article
Abstract: A total of 37 new drug entities were approved in 2022; although that year registered the lowest number of drug approvals since 2016, the TIDES class consolidated its presence with a total of five authorizations (four peptides and one oligonucleotide). Interestingly, 23 out of 37 drugs were first-in-class and thus received fast-track designation by the FDA in categories such as breakthrough therapy, priority review voucher, orphan drug, accelerated approval, and so on. Here, we analyze the TIDES approved in 2022 on the basis of their chemical structure, medical target, mode of action, administration route, and common adverse effects.
Issue Date: 22-Feb-2023
Date of Acceptance: 20-Feb-2023
URI: http://hdl.handle.net/10044/1/103248
DOI: 10.3390/ph16030336
ISSN: 1424-8247
Publisher: MDPI AG
Journal / Book Title: Pharmaceuticals
Volume: 16
Issue: 3
Copyright Statement: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Publication Status: Published
Article Number: ARTN 336
Appears in Collections:Chemical Engineering
Faculty of Engineering



This item is licensed under a Creative Commons License Creative Commons